{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "", "original": "By GRETCHEN MORGENSON", "person": [{"rank": 1, "role": "reported", "firstname": "Gretchen", "organization": "", "lastname": "MORGENSON"}]}, "abstract": "Gretchen Morgenson Fair Game column explains second way Valeant Pharmaceuticals International benefited from its highly questionable drug pricing policies; notes firm's excessive drug price increases also inflated its operating cash flow through so-called price appreciation credits, practice in which company receives credit from wholesalers reflecting impact of that price increase on those wholesalers' current inventory. ", "type_of_material": "News", "word_count": "1167", "lead_paragraph": "It wasn\u2019t just soaring drug prices that helped Valeant Pharmaceuticals\u2019 cash flow. A credit for inventories at those higher prices also plumped the figures.", "pub_date": "2016-07-29T17:25:32+0000", "document_type": "article", "slideshow_credits": null, "headline": {"main": "How Valeant Cashed In Twice on Higher Drug Prices", "content_kicker": "Fair Game", "print_headline": "Two Bumps From One Price Jump", "kicker": "Fair Game"}, "snippet": "It wasn\u2019t just soaring drug prices that helped Valeant Pharmaceuticals\u2019 cash flow. A credit for inventories at those higher prices also plumped the figures....", "multimedia": [{"height": 126, "url": "images/2016/07/31/business/31gret1/31gret1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/07/31/business/31gret1/31gret1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/07/31/business/31gret1/31gret1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/07/31/business/31gret1/31gret1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/07/31/business/31gret1/31gret1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/07/31/business/31gret1/31gret1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/07/31/business/how-valeant-cashed-in-twice-on-higher-drug-prices.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}], "blog": [], "_id": "579b918e38f0d83c0fcf7790", "source": "The New York Times"}